Drug Trial Radar · NCT01371838
A Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia
Last checked: Nov 19, 2026Latest source record: Sep 6, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
848
Actual
Start
Dec 2011
Primary completion
May 2013
Study completion May 2013
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- Collaborators
- Forest Laboratories
- First posted
- Jun 13, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 150 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This purpose of this study is to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia.
Conditions
- Community-Acquired Bacterial Pneumonia
- Lung Infection of Individual Not Recently Hospitalized
Interventions
CeftarolineDrug
Two consecutive infusions q12h for 5 to 7 days
CeftriaxoneDrug
One dose infusion followed by IV saline placebo infused q24h for 5 to 7 days plus two consecutive saline placebo infusion q24h.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Cure Rate for Ceftaroline Compared to That for Ceftriaxone at Test of Cure (TOC) in CE PopulationTime frame: 7-20 days after last dose of study drug
Locations
43 sites in 5 countries. Site status is shown where the registry gives one.
Research Site
Beijing, China
Research Site
Chengdu, China
Research Site
Guangzhou, China
Research Site
Haikou, China
Research Site
Hangzhou, China
Research Site
Hefei, China
Research Site
Jiangyin, China
Research Site
Nanchang, China
Research Site
Shanghai, China
Research Site
Shenyang, China
Research Site
Shenzhen, China
Research Site
Shijiazhuang, China
Research Site
Wuxi, China
Research Site
Bangalore, India
Research Site
Calicut, India
Research Site
Goa, India
Research Site
Hyderabad, India
Research Site
Jaipur, India
Research Site
Lucknow, India
Research Site
Ludhiana, India
Research Site
Mysore, India
Research Site
New Delhi, India
Research Site
Trivandrum, India
Research Site
Varanasi, India
Research Site
Vellore, India
Research Site
Anyang-si, South Korea
Research Site
Bucheon-si, South Korea
Research Site
Cheonan-si, South Korea
Research Site
Chuncheon, South Korea
Research Site
Daegu, South Korea
Research Site
Daejeon, South Korea
Research Site
Incheon, South Korea
Research Site
Seoul, South Korea
Research Site
Suwon, South Korea
Research Site
Wŏnju, South Korea
Research Site
Kaohsiung City, Taiwan
Research Site
Keelung, Taiwan
Research Site
Taichung, Taiwan
Research Site
Taipei, Taiwan
Research Site
Can Tho, Vietnam
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.